ADGM

Adagio Medical Holdings, Inc. (ADGM) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Adagio Medical Holdings, Inc. is a medical technology company developing ablation technologies for cardiac arrhythmias, specifically ventricular tachycardia (VT), using its proprietary Ultra-Low Temperature Ablation (ULTA) platform. The company is currently focused on its FULCRUM-VT U.S. Investigational Device Exemption (IDE) Pivotal Study, which completed enrollment in October 2025. In April 2026, the FDA granted IDE approval to expand the trial to evaluate a next-generation vCLAS system. The company has received CE Mark approval in Europe but paused its limited European commercial launch in February 2025 to prioritize U.S. regulatory approval.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by $2.2 million (30%) to $5.2 million. Research and Development (R&D) expenses declined 25% to $2.7 million, driven by lower clinical trial and product development costs. Selling, General, and Administrative (SG&A) expenses decreased 29% to $2.5 million due to reduced professional services and payroll costs.
• Non-Operating Items: The company recorded a $1.1 million loss from the fair value adjustment of convertible notes, compared to a $0.2 million gain in the prior year. Warrant liabilities fair value adjustment resulted in a $0.1 million loss, compared to a $0.04 million gain previously.
• Liquidity: Cash balances decreased by approximately $4.2 million during the quarter. The company reported a net loss of $7.0 million, partially offset by non-cash adjustments including $1.1 million in convertible note fair value changes and $0.4 million in stock-based compensation.

Guidance, Outlook, and Risks

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. As of March 31, 2026, cash resources are estimated to fund operations only into the third quarter of 2026. The company does not believe existing cash is sufficient for the next 12 months.
• Outlook: The company plans to submit FULCRUM-VT trial results to the FDA in the first half of 2026 and share six-month efficacy results at the Heart Rhythm 2026 Conference in April 2026. Future funding will likely require public or private equity offerings, debt financing, or strategic collaborations.
• Risks: Key risks include the inability to raise additional capital on acceptable terms, delays in regulatory approvals, and the impact of political changes on FDA capacity and tariffs. The company is executing cost-cutting measures to manage cash burn.
• Unusual Items: The company elected the fair value option for its Convertible Securities Notes, resulting in significant volatility in the income statement due to fair value adjustments ($1.1 million loss in Q1 2026).

Investor Verification Checklist

• Cash Runway: Verify the timeline for the next financing round given the "substantial doubt" disclosure and the projection of funds lasting only into Q3 2026.
• Convertible Note Terms: Review the terms of the $20 million Convertible Securities Notes (13% interest, $10.00 conversion price) and the impact of fair value adjustments on reported losses.
• Clinical Trial Status: Confirm the timeline for the release of FULCRUM-VT six-month efficacy data and the subsequent FDA submission schedule.
• Dilution Potential: Assess the dilution impact of outstanding warrants (Base, Convert, and Milestone Warrants) and the 2025 PIPE Pre-Funded Warrants, which total over 43 million potentially dilutive securities.
• Revenue Strategy: Understand the implications of the paused European commercial launch and the reliance on U.S. FDA approval for future revenue generation.